Business / Finance

RSS

Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing and Sourcing Powerhouse

Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing and Sourcing Powerhouse

Actylis Integrates Aceto and its 10 Acquired Specialists with Broad Expertise in GMP and Non-GMP Raw Material Manufacturing and Sourcing into a Singular Global Brand

From Actylis 28 Sep 2022

Specialized Space for Industry Innovation by The European Science Park Group

Specialized Space for Industry Innovation by The European Science Park Group

ESPG AG – European Science Park Group – is one of the first German real estate companies to specialize in the ownership, management, and acquisition of science parks.

21 Sep 2022

ValitaCell joins Beckman Coulter Life Sciences

ValitaCell joins Beckman Coulter Life Sciences

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announces it has acquired ValitaCell Ltd., a biotechnology company that creates pioneering analytical products and technologies for the biopharmaceutical industry.

From Beckman Coulter Life Sciences 16 Sep 2022

AbbVie to present data from its robust migraine portfolio at the Migraine Trust International Symposium 2022

AbbVie to present data from its robust migraine portfolio at the Migraine Trust International Symposium 2022

AbbVie today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS) 2022, taking place in London from September 8-11.

From AbbVie 8 Sep 2022

H.E.L Group strengthens leadership team to focus on new product development and enhanced customer support

H.E.L Group strengthens leadership team to focus on new product development and enhanced customer support

Alan Lockley joins as Director of Global Services, Edward Quinn as Director of Product Development and Mark Appleton takes new role as Director of Research

From H.E.L Group 6 Sep 2022

Inventia Life Science Accelerates Growth with AU$35 million Series B Led by Blackbird Ventures, Launching 3D Cell Culture Platform into US Market

Inventia Life Science Accelerates Growth with AU$35 million Series B Led by Blackbird Ventures, Launching 3D Cell Culture Platform into US Market

Company aims to democratise access to affordable biomedical research especially in cancer research and new drug development through its novel 3D cell culture platform.

From Inventia Life Science 16 Aug 2022

Australian company accelerating the speed of drug discovery wins prestigious Eureka prize

Australian company accelerating the speed of drug discovery wins prestigious Eureka prize

Inventia Life Science announced that its RASTRUM™ 3D cell culture platform has won the ANSTO Eureka Prize for Innovative Use of Technology at the 2021 Australian Museum Eureka Prizes.

From Inventia Life Science 16 Aug 2022

Inventia Life Science partners with Xylyx Bio to develop tissue-specific, digitally-printed bioinks for drug discovery

Inventia Life Science partners with Xylyx Bio to develop tissue-specific, digitally-printed bioinks for drug discovery

Inventia Life Science and Xylyx Bio today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research.

From Inventia Life Science 16 Aug 2022

Inventia Life Science and BioLamina partner to advance cell matrices for complex 3D cell models

Inventia Life Science and BioLamina partner to advance cell matrices for complex 3D cell models

As a result of this partnership, Inventia Life Science will now offer BioLamina’s extensive range of Biolaminin® products incorporated into the pre-validated library of RASTRUM™ Matrices, recapitulating the key motifs found in the native tissue of various cell types.

From Inventia Life Science 16 Aug 2022

Inventia Life Science Announces Partnership with PhenoVista Biosciences to Accelerate Preclinical Research with 3D Cell Models

Inventia Life Science Announces Partnership with PhenoVista Biosciences to Accelerate Preclinical Research with 3D Cell Models

Inventia Life Science, a leader in automated generation of complex 3D cell models, and PhenoVista Biosciences, a top provider of custom imaging-based phenotypic assay services, have entered into a partnership to deliver high-content cell-based assay services for drug discovery.

From Inventia Life Science 16 Aug 2022

RASTRUM™ - the 3D Printer of Living Cells, Honored in Annual Awards by Leading Business Magazine

RASTRUM™ - the 3D Printer of Living Cells, Honored in Annual Awards by Leading Business Magazine

RASTRUM™ has taken out the top prize in the Experimental category. RASTRUM™ prints human cells into living tissue models to supercharge research into cancer and other diseases using revolutionary drop-on-demand technology.

From Inventia Life Science 16 Aug 2022

Evonetix commences early access program for DNA synthesised by thermal control on its semiconductor chip

Evonetix commences early access program for DNA synthesised by thermal control on its semiconductor chip

Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform.

From Evonetix 16 Aug 2022

Azenta announces agreement to acquire B Medical Systems

Azenta announces agreement to acquire B Medical Systems

Azenta, Inc. today announced that it has entered into a definitive agreement to acquire B Medical Systems S.á r.l and its subsidiaries (“B Medical”), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments across the globe.

From B Medical Systems S.à r.l 16 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Vast majority of Brits concerned about equal access to healthcare following pandemic, says 3M

Vast majority of Brits concerned about equal access to healthcare following pandemic, says 3M

80% of Brits say ensuring equal access to quality healthcare is a top priority for society in the next five years.

From 3M 19 Jul 2022

CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities

CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities

State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services.

From CN-Bio 19 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 19 Jul 2022

’Health is Wealth’ focus for global healthcare trade and export summit at Birmingham 2022

’Health is Wealth’ focus for global healthcare trade and export summit at Birmingham 2022

A major trade summit exploring opportunities for data driven healthcare to improve health worldwide will take place at UK House.

15 Jul 2022

INTEGRA pipettes simplify PCR testing for COVID-19

INTEGRA pipettes simplify PCR testing for COVID-19

Matrix Diagnostics – a dedicated COVID-19 testing lab in California – is relying on INTEGRA Biosciences’ EVOLVE and MINI 96 pipettes to streamline and accelerate its PCR workflows

From INTEGRA Biosciences 21 Jun 2022

INTEGRA solutions helping to support a new generation of RNA sequencing

INTEGRA solutions helping to support a new generation of RNA sequencing

INTEGRA Biosciences’ electronic handheld pipetting solutions are helping to improve the throughput capacity of bulk RNA barcoding and sequencing (BRB-seq) at Alithea Genomics in Switzerland.

From INTEGRA Biosciences 17 Jun 2022

Previous
1
...
10
11
12
13
14
15
16
...
372
Next

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.